Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
Scientists from the University of Cambridge in the UK have discovered a mutant form of an immune protein is able to block infection and spread of the human immunodeficiency virus (HIV) in immune cells. Their findings could lead to new ways to fight HIV by offering a new target for drug developers.
A report on the study appears in the latest online issue of the journal Retrovirology.
Senior author Professor Chris Rudd, of the University's Department of Pathology, says:
"One exciting aspect about this new target for HIV intervention is that we should be able to fight HIV without compromising the immune system's ability to battle infections."
The World Health Organisation (WHO) estimates there are over 35 million people living with HIV today. In the last 30 years, the virus has killed over 25 million people.
And although there has been dramatic progress in fighting the virus, with new infections dropping by a third in 2012 compared with 2001, HIV remains a major global public health problem.
HIV attacks T cells, a type of white blood cell that plays a major role in the immune system.
The virus enters T cells by binding to one of their surface receptors, CD4. Once inside, HIV hijacks cell resources and uses them to rapidly replicate itself and release the copies to infect other T cells.
The spread occurs when an infected T cell is attached to an uninfected cell.
In this study, the researchers investigated an immune cell protein called adhesion and degranulation-promoting adaptor protein (ADAP) because it is already known that ADAP is involved in regulating T cell adhesion and proliferation.
But they note despite this knowledge, little has been uncovered about any links between ADAP and infection by HIV.
Their study is the first to show that ADAP regulates infection by HIV-1 via two distinct mechanisms: virus replication within T cells and virus spread due to contact between infected and uninfected T cells.
And they also discovered that a particular mutant form of ADAP is able to interfere with HIV-1 infection by blocking these two mechanisms.
Prof. Rudd says:
"The ADAP mutant is potent in its interference of HIV-1 transmission because it targets simultaneously two critical events, viral replication and the spread of the virus from one T cell to another."
He suggests one treatment possibility could be to give HIV-infected individuals T cells expressing the mutant protein.
In another remarkable study published recently, an international team revealed how they eradicated HIV in cells with an antifungal drug.
Written by Catharine Paddock PhD
Copyright: Medical News Today
Not to be reproduced without the permission of Medical News Today.
Immune adaptor ADAP in T cells regulates HIV-1 transcription and cell-cell viral spread via different co-receptors; Bin Wei, Lei Han, Truus E Abbink, Elisabetta Groppelli, Daina Lim, Youg Raj Thaker, Wei Gao, Rongrong Zhai, Jianhua Wang, Andrew Lever, Clare Jolly, Hongyan Wang and Christopher E Rudd; Retrovirology, published online 18 September 2013; DOI: 10.1186/1742-4690-10-101; Abstract
Additional source: University of Cambridge news release 1 October 2013.
Visit our HIV / AIDS category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Paddock, Catharine. "Mutant protein blocks HIV infection." Medical News Today. MediLexicon, Intl., 2 Oct. 2013. Web.
9 Dec. 2013. <http://www.medicalnewstoday.com/articles/266871>
Paddock, C. (2013, October 2). "Mutant protein blocks HIV infection." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact the our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/articles/266871.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2013 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.